Regeneron Pharmaceuticals, Inc. (REGN) 10-Year Financial Performance & Capital Metrics

REGN •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Show more

Revenue $14.34B +1.0%
EBITDA $4.22B -5.6%
Net Income $4.5B +2.1%
EPS (Diluted) 41.48 +8.2%
Gross Margin 86.27% +0.2%
EBITDA Margin 29.45% -6.5%
Operating Margin 25.75% -8.4%
Net Margin 31.41% +1.1%
ROE 14.87% -6.8%
ROIC 12.4% +15.0%
Debt/Equity 0.09 -6.0%
Interest Coverage 84.31 +16.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 28.4% free cash flow margin
✓Strong 5Y sales CAGR of 11.0%
✓Good 3Y average ROE of 15.7%
✓Share count reduced 5.6% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.33%

5Y11.04%

3Y5.62%

TTM0.99%

Profit (Net Income) CAGR

10Y21.62%

5Y5.1%

3Y1.26%

TTM2.09%

EPS CAGR

10Y22.35%

5Y6.33%

3Y2.77%

TTM8.57%

ROCE

10Y Avg24.16%

5Y Avg22.27%

3Y Avg12.99%

Latest10.78%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	4.86B	5.87B	6.71B	6.56B	8.5B	16.07B	12.17B	13.12B	14.2B	14.34B
Revenue Growth %	18.44%	20.82%	14.28%	-2.28%	29.58%	89.14%	-24.26%	7.76%	8.27%	0.99%
Cost of Goods Sold+	404.44M	542.53M	582.3M	975.4M	1.36B	2.72B	1.71B	2.24B	1.97B	1.97B
COGS % of Revenue	8.32%	9.24%	8.68%	14.87%	15.96%	16.95%	14.01%	17.11%	13.87%	13.73%
Gross Profit+	4.46B	5.33B	6.13B	5.58B	7.14B	13.35B	10.47B	10.87B	12.23B	12.37B
Gross Margin %	91.68%	90.76%	91.32%	85.13%	84.04%	83.05%	85.99%	82.89%	86.13%	86.27%
Gross Profit Growth %	22.55%	19.61%	14.99%	-8.91%	27.93%	86.91%	-21.58%	3.87%	12.5%	1.16%
Operating Expenses+	3.13B	3.25B	3.59B	3.37B	3.56B	4.4B	5.08B	6.52B	8.24B	8.68B
OpEx % of Revenue	64.3%	55.35%	53.56%	51.43%	41.95%	27.38%	41.75%	49.74%	58.03%	60.53%
Selling, General & Admin	1.18B	1.32B	1.56B	1.34B	1.35B	1.82B	2.12B	2.54B	2.95B	2.7B
SG&A % of Revenue	24.23%	22.49%	23.19%	20.46%	15.84%	11.35%	17.38%	19.36%	20.8%	18.82%
Research & Development	1.95B	1.93B	2.04B	2.24B	2.5B	2.62B	3.06B	3.99B	5.23B	5.85B
R&D % of Revenue	40.07%	32.86%	30.37%	34.15%	29.41%	16.31%	25.11%	30.39%	36.85%	40.79%
Other Operating Expenses	0	0	0	-209.2M	-280.4M	-45.6M	-89.9M	-2.1M	53.4M	130.9M
Operating Income+	1.33B	2.08B	2.53B	2.21B	3.58B	8.95B	5.39B	4.35B	3.99B	3.69B
Operating Margin %	27.38%	35.41%	37.77%	33.7%	42.09%	55.67%	44.24%	33.15%	28.1%	25.75%
Operating Income Growth %	6.3%	56.27%	21.87%	-12.81%	61.85%	150.15%	-39.8%	-19.26%	-8.23%	-7.46%
EBITDA+	1.44B	2.23B	2.68B	2.42B	3.81B	9.23B	5.73B	4.77B	4.47B	4.22B
EBITDA Margin %	29.53%	37.89%	39.97%	36.91%	44.87%	57.45%	47.05%	36.36%	31.5%	29.45%
EBITDA Growth %	8.19%	55%	20.56%	-9.79%	57.53%	142.18%	-37.97%	-16.72%	-6.21%	-5.57%
D&A (Non-Cash Add-back)	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M	531.6M
EBIT	1.34B	2.1B	2.58B	2.46B	3.87B	9.38B	4.92B	4.27B	4.84B	5.27B
Net Interest Income+	-7.2M	-25.12M	-28.2M	-30.2M	-56.9M	-57.3M	100.7M	422.9M	656.2M	-43.8M
Interest Income	0	0	0	0	0	0	160.1M	495.9M	711.4M	0
Interest Expense	7.2M	25.12M	28.2M	30.2M	56.9M	57.3M	59.4M	73M	55.2M	43.8M
Other Income/Expense	-926K	-1.08M	19.1M	219.3M	233.8M	379M	-526.8M	-149.3M	789.2M	1.54B
Pretax Income+	1.33B	2.08B	2.55B	2.43B	3.81B	9.33B	4.86B	4.2B	4.78B	5.23B
Pretax Margin %	27.36%	35.4%	38.05%	37.04%	44.84%	58.03%	39.91%	32.01%	33.66%	36.47%
Income Tax+	434.29M	880M	109.1M	313.3M	297.2M	1.25B	520.4M	245.7M	367.3M	725.8M
Effective Tax Rate %	67.34%	57.66%	95.73%	87.1%	92.2%	86.59%	89.29%	94.15%	92.32%	86.12%
Net Income+	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Net Margin %	18.42%	20.41%	36.42%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%	31.41%
Net Income Growth %	40.79%	33.83%	103.95%	-13.44%	66.05%	129.86%	-46.28%	-8.87%	11.61%	2.09%
Net Income (Continuing)	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	7.70	10.34	21.29	18.46	30.52	71.97	38.22	34.77	38.34	41.48
EPS Growth %	39.49%	34.29%	105.9%	-13.29%	65.33%	135.81%	-46.89%	-9.03%	10.27%	8.19%
EPS (Basic)	8.55	11.27	21.29	19.38	32.65	76.40	40.51	37.05	40.90	43.07
Diluted Shares Outstanding	116.3M	115.91M	114.8M	114.6M	115.1M	112.2M	113.5M	113.7M	115.1M	108.6M
Basic Shares Outstanding	116.25M	115.9M	114.8M	109.2M	107.6M	105.7M	107.1M	106.7M	107.9M	104.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	3.91B	5.6B	7.96B	7.69B	9.78B	14.01B	15.88B	19.48B	18.66B	27.81B
Cash & Short-Term Investments	1.04B	1.41B	2.81B	3.21B	3.59B	5.69B	7.74B	10.84B	9.01B	18.87B
Cash Only	535.2M	812.73M	1.47B	1.62B	2.19B	2.89B	3.11B	2.73B	2.49B	18.87B
Short-Term Investments	503.48M	596.85M	1.34B	1.6B	1.39B	2.81B	4.64B	8.11B	6.52B	0
Accounts Receivable	1.61B	1.97B	2.24B	2.79B	4.11B	6.04B	5.33B	5.67B	6.21B	5.74B
Days Sales Outstanding	121.03	122.72	122.01	155.05	176.75	137.09	159.78	157.7	159.65	146.1
Inventory	399.36M	726.14M	1.15B	1.42B	1.92B	1.95B	2.4B	2.58B	3.09B	3.2B
Days Inventory Outstanding	360.41	488.53	721.6	529.69	515.98	261.49	514.13	419.64	571.87	593.34
Other Current Assets	0	0	0	0	0	0	0	386.6M	349.2M	0
Total Non-Current Assets+	3.79B	4.43B	5.29B	7.12B	7.38B	11.42B	13.33B	13.6B	19.1B	12.75B
Property, Plant & Equipment	2.08B	2.36B	2.58B	2.89B	3.22B	3.48B	3.76B	4.15B	4.6B	5.12B
Fixed Asset Turnover	2.33x	2.49x	2.61x	2.27x	2.64x	4.62x	3.23x	3.16x	3.09x	2.80x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	6.7M	915.5M	1.04B	1.15B	1.26B
Long-Term Investments	864.26M	1.49B	1.75B	3.26B	3.14B	6.84B	6.59B	5.4B	8.9B	0
Other Non-Current Assets	20.29M	77.9M	127.4M	144.7M	168.1M	216.1M	336.4M	444.1M	1.14B	2.3B
Total Assets+	6.97B	8.76B	11.73B	14.81B	17.16B	25.43B	29.21B	33.08B	37.76B	40.56B
Asset Turnover	0.70x	0.67x	0.57x	0.44x	0.50x	0.63x	0.42x	0.40x	0.38x	0.35x
Asset Growth %	24.32%	25.68%	33.89%	26.17%	15.93%	48.19%	14.86%	13.23%	14.14%	7.41%
Total Current Liabilities+	1.24B	1.14B	1.44B	2.1B	2.7B	3.93B	3.14B	3.42B	3.94B	5.83B
Accounts Payable	134.98M	178.2M	218.2M	418.1M	475.5M	564M	589.2M	606.6M	789.5M	5.83B
Days Payables Outstanding	121.82	119.89	136.77	156.46	128.01	75.58	126.12	98.65	146.24	1.08K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	231.66M	320.14M	452.5M	591.7M	577.7M	442M	477.9M	458.9M	627.7M	553M
Other Current Liabilities	1.18M	0	0	85M	0	0	0	0	0	-553M
Current Ratio	3.15x	4.93x	5.52x	3.67x	3.63x	3.56x	5.06x	5.69x	4.73x	4.77x
Quick Ratio	2.83x	4.29x	4.72x	2.99x	2.91x	3.07x	4.29x	4.94x	3.95x	4.22x
Cash Conversion Cycle	359.62	491.36	706.83	528.28	564.71	323	547.79	478.69	585.28	-342.06
Total Non-Current Liabilities+	1.28B	1.48B	1.53B	1.62B	3.44B	2.73B	3.41B	3.68B	4.46B	3.47B
Long-Term Debt	0	0	0	0	1.98B	1.98B	1.98B	1.98B	1.98B	1.99B
Capital Lease Obligations	351.57M	703.5M	708.5M	713.9M	717.2M	0	720M	720M	720M	720M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	100.39M	949.29M	546.6M	799.7M	687.1M	680.2M	638M	854.1M	1.57B	0
Total Liabilities	2.52B	2.62B	2.98B	3.72B	6.14B	6.67B	6.55B	7.11B	8.41B	9.3B
Total Debt+	481.13M	703.45M	708.5M	713.9M	2.7B	2.7B	2.7B	2.7B	2.7B	2.71B
Net Debt	-54.08M	-109.28M	-759.2M	-903.9M	502M	-185.9M	-404.5M	-27.1M	216.2M	-16.16B
Debt / Equity	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x	0.09x
Debt / EBITDA	0.34x	0.32x	0.26x	0.29x	0.71x	0.29x	0.47x	0.57x	0.60x	0.64x
Net Debt / EBITDA	-0.04x	-0.05x	-0.28x	-0.37x	0.13x	-0.02x	-0.07x	-0.01x	0.05x	-3.83x
Interest Coverage	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x	84.31x
Total Equity+	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B	31.26B
Equity Growth %	21.74%	38.09%	42.53%	26.63%	-0.58%	70.23%	20.75%	14.6%	13.02%	6.48%
Book Value per Share	38.26	53.01	76.28	96.77	95.79	167.28	199.68	228.44	255.03	287.82
Total Shareholders' Equity	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B	31.26B
Common Stock	110K	112K	100K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	1.75B	2.95B	5.25B	7.38B	10.89B	18.97B	23.31B	27.26B	31.67B	35.8B
Treasury Stock	-316.24M	-316.24M	-396.4M	-739.9M	-6.61B	-8.26B	-10.35B	-12.56B	-15.17B	-17.94B
Accumulated OCI	-12.84M	640K	-12.3M	21.1M	29.3M	-26.2M	-238.8M	-80.9M	-7.9M	77.5M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	1.49B	1.31B	2.2B	2.43B	2.62B	7.08B	5.01B	4.59B	4.42B	4.98B
Operating CF Margin %	30.57%	22.26%	32.71%	37.06%	30.81%	44.06%	41.2%	35.02%	31.13%	34.71%
Operating CF Growth %	11.66%	-12.03%	67.94%	10.7%	7.74%	170.47%	-29.18%	-8.39%	-3.78%	12.63%
Net Income	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Depreciation & Amortization	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M	543.7M
Stock-Based Compensation	559.88M	507.28M	427.4M	464.3M	432M	601.7M	725M	885M	982.8M	993.7M
Deferred Taxes	-360.08M	318.81M	-140M	-130.6M	75.6M	-147.1M	-746.4M	-837.8M	-757.3M	-785.4M
Other Non-Cash Items	57.64M	63.57M	12.1M	-29.3M	-135M	181.7M	599.8M	266.3M	-82.2M	-278M
Working Capital Changes	228.19M	-926.53M	-697M	-200.5M	-1.5B	-1.92B	-243.3M	-94.1M	-618.3M	0
Change in Receivables	-143.83M	-362.72M	-268.9M	-473.1M	-1.36B	-1.93B	707.8M	-338.8M	-554M	498.1M
Change in Inventory	-149.78M	-314.19M	-387.9M	-335.5M	-529.4M	-494.3M	-696.5M	-271.7M	-619.7M	-275.3M
Change in Payables	253.98M	-23.19M	210M	444.5M	118.9M	866.1M	-138.4M	598.6M	735.1M	736.8M
Cash from Investing+	-1.05B	-1.01B	-1.46B	-2.03B	-70.6M	-5.38B	-3.78B	-3.19B	-2.47B	-629.1M
Capital Expenditures	-511.9M	-272.6M	-383.1M	-429.6M	-614.6M	-551.9M	-590.1M	-926.4M	-755.9M	-898.4M
CapEx % of Revenue	10.53%	4.64%	5.71%	6.55%	7.23%	3.43%	4.85%	7.06%	5.32%	6.26%
Acquisitions	0	0	1.07B	429.6M	614.6M	551.9M	-230.3M	-54.9M	-16.5M	-3.3M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-41K	-26K	-1.08B	-429.6M	-614.6M	-551.9M	-1.03B	0	-105.6M	-315.3M
Cash from Financing+	-700.39M	-24.4M	-77.1M	-252.1M	-1.97B	-1.01B	-1.01B	-1.79B	-2.2B	-3.72B
Debt Issued (Net)	-40.6M	37.1M	0	0	1.98B	0	0	0	0	0
Equity Issued (Net)	-1000K	-1000K	1000K	-1000K	-1000K	1000K	-1000K	-1000K	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	-370.3M
Share Repurchases	-143.2M	-301.7M	-191.6M	-463.9M	-6.53B	-2.68B	-2.53B	-2.94B	-3.63B	-3.44B
Other Financing	-516.59M	0	-187.2M	-188M	2.58B	-1.03B	-445.7M	0	-33.4M	-3.35B
Net Change in Cash	-273.9M	277.53M	655M	150.1M	577M	690.8M	221.3M	-381.6M	-248.8M	634.7M
Free Cash Flow+	974M	1.03B	1.81B	2B	2B	6.53B	4.42B	3.67B	3.66B	4.08B
FCF Margin %	20.04%	17.62%	27%	30.51%	23.58%	40.63%	36.35%	27.96%	25.8%	28.45%
FCF Growth %	49.19%	6.21%	75.16%	10.4%	0.15%	225.9%	-32.23%	-17.11%	-0.08%	11.35%
FCF per Share	8.37	8.93	15.78	17.46	17.41	58.19	38.99	32.26	31.84	37.57
FCF Conversion (FCF/Net Income)	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x	1.11x
Interest Paid	5.5M	18.7M	22.3M	25M	23.2M	55.8M	53.7M	73.1M	52.6M	0
Taxes Paid	481.4M	754.8M	205.6M	342.3M	188.1M	1.22B	1.5B	870.3M	743M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	22.1%	22.63%	32.81%	21.32%	31.77%	54.21%	20.94%	16.26%	15.95%	14.87%
Return on Invested Capital (ROIC)	26.21%	29.91%	27.09%	18.23%	24.71%	44.57%	19.78%	13.53%	10.78%	12.4%
Gross Margin	91.68%	90.76%	91.32%	85.13%	84.04%	83.05%	85.99%	82.89%	86.13%	86.27%
Net Margin	18.42%	20.41%	36.42%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%	31.41%
Debt / Equity	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x	0.09x
Interest Coverage	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x	84.31x
FCF Conversion	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x	1.11x
Revenue Growth	18.44%	20.82%	14.28%	-2.28%	29.58%	89.14%	-24.26%	7.76%	8.27%	0.99%

US Stock Screener

...

Regeneron Pharmaceuticals, Inc. (REGN) 10-Year Financial Performance & Capital Metrics

REGN •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $14.34B +1.0%
EBITDA $4.22B -5.6%
Net Income $4.5B +2.1%
EPS (Diluted) 41.48 +8.2%
Gross Margin 86.27% +0.2%
EBITDA Margin 29.45% -6.5%
Operating Margin 25.75% -8.4%
Net Margin 31.41% +1.1%
ROE 14.87% -6.8%
ROIC 12.4% +15.0%
Debt/Equity 0.09 -6.0%
Interest Coverage 84.31 +16.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 28.4% free cash flow margin
✓Strong 5Y sales CAGR of 11.0%
✓Good 3Y average ROE of 15.7%
✓Share count reduced 5.6% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.33%

5Y11.04%

3Y5.62%

TTM0.99%

Profit (Net Income) CAGR

10Y21.62%

5Y5.1%

3Y1.26%

TTM2.09%

EPS CAGR

10Y22.35%

5Y6.33%

3Y2.77%

TTM8.57%

ROCE

10Y Avg24.16%

5Y Avg22.27%

3Y Avg12.99%

Latest10.78%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	4.86B	5.87B	6.71B	6.56B	8.5B	16.07B	12.17B	13.12B	14.2B	14.34B
Revenue Growth %	18.44%	20.82%	14.28%	-2.28%	29.58%	89.14%	-24.26%	7.76%	8.27%	0.99%
Cost of Goods Sold+	404.44M	542.53M	582.3M	975.4M	1.36B	2.72B	1.71B	2.24B	1.97B	1.97B
COGS % of Revenue	8.32%	9.24%	8.68%	14.87%	15.96%	16.95%	14.01%	17.11%	13.87%	13.73%
Gross Profit+	4.46B	5.33B	6.13B	5.58B	7.14B	13.35B	10.47B	10.87B	12.23B	12.37B
Gross Margin %	91.68%	90.76%	91.32%	85.13%	84.04%	83.05%	85.99%	82.89%	86.13%	86.27%
Gross Profit Growth %	22.55%	19.61%	14.99%	-8.91%	27.93%	86.91%	-21.58%	3.87%	12.5%	1.16%
Operating Expenses+	3.13B	3.25B	3.59B	3.37B	3.56B	4.4B	5.08B	6.52B	8.24B	8.68B
OpEx % of Revenue	64.3%	55.35%	53.56%	51.43%	41.95%	27.38%	41.75%	49.74%	58.03%	60.53%
Selling, General & Admin	1.18B	1.32B	1.56B	1.34B	1.35B	1.82B	2.12B	2.54B	2.95B	2.7B
SG&A % of Revenue	24.23%	22.49%	23.19%	20.46%	15.84%	11.35%	17.38%	19.36%	20.8%	18.82%
Research & Development	1.95B	1.93B	2.04B	2.24B	2.5B	2.62B	3.06B	3.99B	5.23B	5.85B
R&D % of Revenue	40.07%	32.86%	30.37%	34.15%	29.41%	16.31%	25.11%	30.39%	36.85%	40.79%
Other Operating Expenses	0	0	0	-209.2M	-280.4M	-45.6M	-89.9M	-2.1M	53.4M	130.9M
Operating Income+	1.33B	2.08B	2.53B	2.21B	3.58B	8.95B	5.39B	4.35B	3.99B	3.69B
Operating Margin %	27.38%	35.41%	37.77%	33.7%	42.09%	55.67%	44.24%	33.15%	28.1%	25.75%
Operating Income Growth %	6.3%	56.27%	21.87%	-12.81%	61.85%	150.15%	-39.8%	-19.26%	-8.23%	-7.46%
EBITDA+	1.44B	2.23B	2.68B	2.42B	3.81B	9.23B	5.73B	4.77B	4.47B	4.22B
EBITDA Margin %	29.53%	37.89%	39.97%	36.91%	44.87%	57.45%	47.05%	36.36%	31.5%	29.45%
EBITDA Growth %	8.19%	55%	20.56%	-9.79%	57.53%	142.18%	-37.97%	-16.72%	-6.21%	-5.57%
D&A (Non-Cash Add-back)	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M	531.6M
EBIT	1.34B	2.1B	2.58B	2.46B	3.87B	9.38B	4.92B	4.27B	4.84B	5.27B
Net Interest Income+	-7.2M	-25.12M	-28.2M	-30.2M	-56.9M	-57.3M	100.7M	422.9M	656.2M	-43.8M
Interest Income	0	0	0	0	0	0	160.1M	495.9M	711.4M	0
Interest Expense	7.2M	25.12M	28.2M	30.2M	56.9M	57.3M	59.4M	73M	55.2M	43.8M
Other Income/Expense	-926K	-1.08M	19.1M	219.3M	233.8M	379M	-526.8M	-149.3M	789.2M	1.54B
Pretax Income+	1.33B	2.08B	2.55B	2.43B	3.81B	9.33B	4.86B	4.2B	4.78B	5.23B
Pretax Margin %	27.36%	35.4%	38.05%	37.04%	44.84%	58.03%	39.91%	32.01%	33.66%	36.47%
Income Tax+	434.29M	880M	109.1M	313.3M	297.2M	1.25B	520.4M	245.7M	367.3M	725.8M
Effective Tax Rate %	67.34%	57.66%	95.73%	87.1%	92.2%	86.59%	89.29%	94.15%	92.32%	86.12%
Net Income+	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Net Margin %	18.42%	20.41%	36.42%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%	31.41%
Net Income Growth %	40.79%	33.83%	103.95%	-13.44%	66.05%	129.86%	-46.28%	-8.87%	11.61%	2.09%
Net Income (Continuing)	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	7.70	10.34	21.29	18.46	30.52	71.97	38.22	34.77	38.34	41.48
EPS Growth %	39.49%	34.29%	105.9%	-13.29%	65.33%	135.81%	-46.89%	-9.03%	10.27%	8.19%
EPS (Basic)	8.55	11.27	21.29	19.38	32.65	76.40	40.51	37.05	40.90	43.07
Diluted Shares Outstanding	116.3M	115.91M	114.8M	114.6M	115.1M	112.2M	113.5M	113.7M	115.1M	108.6M
Basic Shares Outstanding	116.25M	115.9M	114.8M	109.2M	107.6M	105.7M	107.1M	106.7M	107.9M	104.6M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	3.91B	5.6B	7.96B	7.69B	9.78B	14.01B	15.88B	19.48B	18.66B	27.81B
Cash & Short-Term Investments	1.04B	1.41B	2.81B	3.21B	3.59B	5.69B	7.74B	10.84B	9.01B	18.87B
Cash Only	535.2M	812.73M	1.47B	1.62B	2.19B	2.89B	3.11B	2.73B	2.49B	18.87B
Short-Term Investments	503.48M	596.85M	1.34B	1.6B	1.39B	2.81B	4.64B	8.11B	6.52B	0
Accounts Receivable	1.61B	1.97B	2.24B	2.79B	4.11B	6.04B	5.33B	5.67B	6.21B	5.74B
Days Sales Outstanding	121.03	122.72	122.01	155.05	176.75	137.09	159.78	157.7	159.65	146.1
Inventory	399.36M	726.14M	1.15B	1.42B	1.92B	1.95B	2.4B	2.58B	3.09B	3.2B
Days Inventory Outstanding	360.41	488.53	721.6	529.69	515.98	261.49	514.13	419.64	571.87	593.34
Other Current Assets	0	0	0	0	0	0	0	386.6M	349.2M	0
Total Non-Current Assets+	3.79B	4.43B	5.29B	7.12B	7.38B	11.42B	13.33B	13.6B	19.1B	12.75B
Property, Plant & Equipment	2.08B	2.36B	2.58B	2.89B	3.22B	3.48B	3.76B	4.15B	4.6B	5.12B
Fixed Asset Turnover	2.33x	2.49x	2.61x	2.27x	2.64x	4.62x	3.23x	3.16x	3.09x	2.80x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	6.7M	915.5M	1.04B	1.15B	1.26B
Long-Term Investments	864.26M	1.49B	1.75B	3.26B	3.14B	6.84B	6.59B	5.4B	8.9B	0
Other Non-Current Assets	20.29M	77.9M	127.4M	144.7M	168.1M	216.1M	336.4M	444.1M	1.14B	2.3B
Total Assets+	6.97B	8.76B	11.73B	14.81B	17.16B	25.43B	29.21B	33.08B	37.76B	40.56B
Asset Turnover	0.70x	0.67x	0.57x	0.44x	0.50x	0.63x	0.42x	0.40x	0.38x	0.35x
Asset Growth %	24.32%	25.68%	33.89%	26.17%	15.93%	48.19%	14.86%	13.23%	14.14%	7.41%
Total Current Liabilities+	1.24B	1.14B	1.44B	2.1B	2.7B	3.93B	3.14B	3.42B	3.94B	5.83B
Accounts Payable	134.98M	178.2M	218.2M	418.1M	475.5M	564M	589.2M	606.6M	789.5M	5.83B
Days Payables Outstanding	121.82	119.89	136.77	156.46	128.01	75.58	126.12	98.65	146.24	1.08K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	231.66M	320.14M	452.5M	591.7M	577.7M	442M	477.9M	458.9M	627.7M	553M
Other Current Liabilities	1.18M	0	0	85M	0	0	0	0	0	-553M
Current Ratio	3.15x	4.93x	5.52x	3.67x	3.63x	3.56x	5.06x	5.69x	4.73x	4.77x
Quick Ratio	2.83x	4.29x	4.72x	2.99x	2.91x	3.07x	4.29x	4.94x	3.95x	4.22x
Cash Conversion Cycle	359.62	491.36	706.83	528.28	564.71	323	547.79	478.69	585.28	-342.06
Total Non-Current Liabilities+	1.28B	1.48B	1.53B	1.62B	3.44B	2.73B	3.41B	3.68B	4.46B	3.47B
Long-Term Debt	0	0	0	0	1.98B	1.98B	1.98B	1.98B	1.98B	1.99B
Capital Lease Obligations	351.57M	703.5M	708.5M	713.9M	717.2M	0	720M	720M	720M	720M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	100.39M	949.29M	546.6M	799.7M	687.1M	680.2M	638M	854.1M	1.57B	0
Total Liabilities	2.52B	2.62B	2.98B	3.72B	6.14B	6.67B	6.55B	7.11B	8.41B	9.3B
Total Debt+	481.13M	703.45M	708.5M	713.9M	2.7B	2.7B	2.7B	2.7B	2.7B	2.71B
Net Debt	-54.08M	-109.28M	-759.2M	-903.9M	502M	-185.9M	-404.5M	-27.1M	216.2M	-16.16B
Debt / Equity	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x	0.09x
Debt / EBITDA	0.34x	0.32x	0.26x	0.29x	0.71x	0.29x	0.47x	0.57x	0.60x	0.64x
Net Debt / EBITDA	-0.04x	-0.05x	-0.28x	-0.37x	0.13x	-0.02x	-0.07x	-0.01x	0.05x	-3.83x
Interest Coverage	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x	84.31x
Total Equity+	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B	31.26B
Equity Growth %	21.74%	38.09%	42.53%	26.63%	-0.58%	70.23%	20.75%	14.6%	13.02%	6.48%
Book Value per Share	38.26	53.01	76.28	96.77	95.79	167.28	199.68	228.44	255.03	287.82
Total Shareholders' Equity	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B	31.26B
Common Stock	110K	112K	100K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	1.75B	2.95B	5.25B	7.38B	10.89B	18.97B	23.31B	27.26B	31.67B	35.8B
Treasury Stock	-316.24M	-316.24M	-396.4M	-739.9M	-6.61B	-8.26B	-10.35B	-12.56B	-15.17B	-17.94B
Accumulated OCI	-12.84M	640K	-12.3M	21.1M	29.3M	-26.2M	-238.8M	-80.9M	-7.9M	77.5M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	1.49B	1.31B	2.2B	2.43B	2.62B	7.08B	5.01B	4.59B	4.42B	4.98B
Operating CF Margin %	30.57%	22.26%	32.71%	37.06%	30.81%	44.06%	41.2%	35.02%	31.13%	34.71%
Operating CF Growth %	11.66%	-12.03%	67.94%	10.7%	7.74%	170.47%	-29.18%	-8.39%	-3.78%	12.63%
Net Income	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B	4.5B
Depreciation & Amortization	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M	543.7M
Stock-Based Compensation	559.88M	507.28M	427.4M	464.3M	432M	601.7M	725M	885M	982.8M	993.7M
Deferred Taxes	-360.08M	318.81M	-140M	-130.6M	75.6M	-147.1M	-746.4M	-837.8M	-757.3M	-785.4M
Other Non-Cash Items	57.64M	63.57M	12.1M	-29.3M	-135M	181.7M	599.8M	266.3M	-82.2M	-278M
Working Capital Changes	228.19M	-926.53M	-697M	-200.5M	-1.5B	-1.92B	-243.3M	-94.1M	-618.3M	0
Change in Receivables	-143.83M	-362.72M	-268.9M	-473.1M	-1.36B	-1.93B	707.8M	-338.8M	-554M	498.1M
Change in Inventory	-149.78M	-314.19M	-387.9M	-335.5M	-529.4M	-494.3M	-696.5M	-271.7M	-619.7M	-275.3M
Change in Payables	253.98M	-23.19M	210M	444.5M	118.9M	866.1M	-138.4M	598.6M	735.1M	736.8M
Cash from Investing+	-1.05B	-1.01B	-1.46B	-2.03B	-70.6M	-5.38B	-3.78B	-3.19B	-2.47B	-629.1M
Capital Expenditures	-511.9M	-272.6M	-383.1M	-429.6M	-614.6M	-551.9M	-590.1M	-926.4M	-755.9M	-898.4M
CapEx % of Revenue	10.53%	4.64%	5.71%	6.55%	7.23%	3.43%	4.85%	7.06%	5.32%	6.26%
Acquisitions	0	0	1.07B	429.6M	614.6M	551.9M	-230.3M	-54.9M	-16.5M	-3.3M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-41K	-26K	-1.08B	-429.6M	-614.6M	-551.9M	-1.03B	0	-105.6M	-315.3M
Cash from Financing+	-700.39M	-24.4M	-77.1M	-252.1M	-1.97B	-1.01B	-1.01B	-1.79B	-2.2B	-3.72B
Debt Issued (Net)	-40.6M	37.1M	0	0	1.98B	0	0	0	0	0
Equity Issued (Net)	-1000K	-1000K	1000K	-1000K	-1000K	1000K	-1000K	-1000K	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	-370.3M
Share Repurchases	-143.2M	-301.7M	-191.6M	-463.9M	-6.53B	-2.68B	-2.53B	-2.94B	-3.63B	-3.44B
Other Financing	-516.59M	0	-187.2M	-188M	2.58B	-1.03B	-445.7M	0	-33.4M	-3.35B
Net Change in Cash	-273.9M	277.53M	655M	150.1M	577M	690.8M	221.3M	-381.6M	-248.8M	634.7M
Free Cash Flow+	974M	1.03B	1.81B	2B	2B	6.53B	4.42B	3.67B	3.66B	4.08B
FCF Margin %	20.04%	17.62%	27%	30.51%	23.58%	40.63%	36.35%	27.96%	25.8%	28.45%
FCF Growth %	49.19%	6.21%	75.16%	10.4%	0.15%	225.9%	-32.23%	-17.11%	-0.08%	11.35%
FCF per Share	8.37	8.93	15.78	17.46	17.41	58.19	38.99	32.26	31.84	37.57
FCF Conversion (FCF/Net Income)	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x	1.11x
Interest Paid	5.5M	18.7M	22.3M	25M	23.2M	55.8M	53.7M	73.1M	52.6M	0
Taxes Paid	481.4M	754.8M	205.6M	342.3M	188.1M	1.22B	1.5B	870.3M	743M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	22.1%	22.63%	32.81%	21.32%	31.77%	54.21%	20.94%	16.26%	15.95%	14.87%
Return on Invested Capital (ROIC)	26.21%	29.91%	27.09%	18.23%	24.71%	44.57%	19.78%	13.53%	10.78%	12.4%
Gross Margin	91.68%	90.76%	91.32%	85.13%	84.04%	83.05%	85.99%	82.89%	86.13%	86.27%
Net Margin	18.42%	20.41%	36.42%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%	31.41%
Debt / Equity	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x	0.09x
Interest Coverage	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x	84.31x
FCF Conversion	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x	1.11x
Revenue Growth	18.44%	20.82%	14.28%	-2.28%	29.58%	89.14%	-24.26%	7.76%	8.27%	0.99%

Regeneron Pharmaceuticals, Inc. (REGN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare REGN vs Peers

vs CNTA

vs IMNM

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Regeneron Pharmaceuticals, Inc. (REGN) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare REGN vs Peers

vs CNTA

vs IMNM

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios